Filenews 11 May 2022
The Ministry of Health announces that as of May 13, 2022, the pharmaceutical product Paxlovid (PF-07321332 150 mg/ ritonavir 100 mg) coated tablets will be available for prescription through the GHS informatics system to patients with laboratory-confirmed (PCR or Rapid Ag Test) mild or moderate COVID-19 disease, who do not require hospitalization due to severe or critical COVID-19 disease, within 5 days from the date of onset of symptoms or the date of testing (whichever has occurred first) and with at least one risk factor.
Prescribing physicians will be asked to answer a questionnaire that will be posted in the GHS's IT System in order to ensure that prescribing will be done only to those patients who meet the criteria set by the ad-hoc Committee of the Ministry of Health for the creation and implementation of the relevant protocols regarding medication against COVID-19.
Paxlovid's prescription can be done by the following doctors:
- Personal Doctors for Adults
- Physicians
- Doctors specializing in Infectious Diseases
- Pulmonologists
- Haematologists
- Pathologists- Oncologists
- Cardiologists
- Nephrologists
- Neurologists
- Rheumatologists
- Endocrinologists
- Geriatricians
- Gastroenterologists
- Oncologists-Radiotherapists
The pharmaceutical product Paxlovid will be available only from the following hospital pharmacies of the CySEC: General Hospitals of Nicosia, Limassol, Larnaca, Famagusta, Paphos and Troodos and Polis Chrysochous Hospitals.
It is also noted that a co-payment (€1) should NOT be collected for the pharmaceutical product Paxlovid.
Important information about Paxlovid:
The medicinal product Paxlovid is authorised on the market by the European Medicines Agency (EMA).
It is required to consult the Summary of Product Characteristics (SmPC) regarding the contraindications, special warnings/precautions and interactions of Paxlovid with other medicinal products.
The SmPC as well as all relevant product information is available at the following link: https://www.ema.europa.eu/en/medicines/human/EPAR/paxlovid#product-information-section
Report of suspected side effects with the drug Paxlovid
Healthcare professionals are asked to report any suspected adverse reactions through the national reporting system to the Pharmaceutical Services of the Ministry of Health by electronic submission to the Yellow Card link or the following contact details:
Pharmaceutical Services Ministry of Health CY-1475 Nicosia Tel: +357 22608607 Fax: + 357 22608669 Website: www.moh.gov.cy/phs
